Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions

计划入组 53 人 · 首次发布于 2016 年 5 月 24 日

Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

计划入组 160 人 · 首次发布于 2025 年 3 月 18 日

To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

计划入组 80 人 · 首次发布于 2024 年 4 月 3 日

Vismodegib(Erivedge)

C₁₉H₁₄Cl₂N₂O₃S · Rx

Sonidegib(Odomzo)

C₂₆H₂₆F₃N₃O₃ · Rx

small molecule therapeutic (basal cell carcinoma)

Gamida Cell

Israel

GAMIDA CELL INC.

United States

CELL GENESYS INC.

United States

Libtayo Gains Widespread Provincial Reimbursement Across Canada for Advanced NSCLC and Basal Cell Carcinoma

Sun Pharma's Sonidegib Shows Promise Across Multiple Cancer Indications Beyond Basal Cell Carcinoma

Real-World Analysis Reveals New Safety Signals for Sonidegib in Basal Cell Carcinoma Treatment